TABLE 3.
Secondary clinical outcomes
| All (n = 40) | Esmolol (n = 18) | Control (n = 22) | P | |
|---|---|---|---|---|
|
| ||||
| Median shock free days (IQR) | 2 (0, 5) | 2 (0, 5) | 2.5 (0, 6) | 0.32 |
| Time to shock reversal (days) | 3.1 (1.7, 6.2) | 3.9 (1.9, 6.5) | 2.5 (1.5, 6.1) | 0.20 |
| Intubated after enrollment (n, %) | 4 (10) | 2 (11) | 2 (9) | >0.99 |
| Hospital mortality (n, %) | 14 (35) | 6 (33) | 8 (36) | >0.99 |
| Dialysis (n, %) | 10 (25) | 3 (17) | 7 (32) | 0.46 |
| Median Hospital LOS in all patients (IQR) | 12 (6, 28) | 10 (6, 25) | 13 (6, 30) | 0.82 |
| Median Hospital LOS in survivors (IQR) | 15 (7, 30) | 13 (7, 29) | 15 (7, 35) | 0.86 |
| Median ICU LOS in all patients (IQR) | 6 (3, 13) | 8 (3, 14) | 6 (3, 12) | 0.44 |
| Median ICU LOS in survivors (IQR) | 5 (3, 11) | 8 (3, 13) | 4 (2, 11) | 0.41 |
| Median Ventilator days in all ventilated patients (IQR) | 6 (3, 12) | 7 (4, 13) | 6 (2, 12) | 0.56 |
| Median Ventilator days in ventilated patients who survived (IQR) | 7 (2, 16) | 7 (3, 16) | 6.5 (1, 13) | 0.56 |
| Fluids during the study (mL, median IQR) | 4916 (2507, 7375) | 6089 (3077, 8715) | 3990 (2027, 7145) | 0.14 |
| Urine output between 0 and 12 h after study start | 488 (267, 1099) | 572 (214, 1300) | 488 (280, 1007) | 0.86 |
| Urine output between 12 and 24 h after study start* | 491 (310, 895) | 508 (310, 1075) | 491 (310, 800) | 0.61 |
*
1 value missing in placebo group.